Search

Displaying results 1321 - 1330 of 5895 in total
  1. Drug

    Ciclesonide

    go.drugbank.com/drugs/DB01410
    ApprovedInvestigational

    Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.

    Categories: Agents to Treat Airway Disease
  2. Drug

    Zucapsaicin

    go.drugbank.com/drugs/DB09120
    ApprovedWithdrawn

    Zucapsaicin, the cis-isomer of capsaicin, is a topical analgesic used to treat osteoarthritis of the knee and other neuropathic pain.

  3. Drug

    Bromocriptine

    go.drugbank.com/drugs/DB01200
    ApprovedInvestigationalWithdrawn

    [L43942,L43947] It continues to be used for the indications mentioned above. … It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia.

    Products: Co Bromocriptine Capsules 5mg, Co Bromocriptine Tablets 2.5mg
  4. Drug

    Valoctocogene roxaparvovec

    go.drugbank.com/drugs/DB15561
    ApprovedInvestigationalWithdrawn

    [A252797] As opposed to these therapies, valoctocogene roxaparvovec offers the advantage of continuous and measurable steady-state levels of coagulation factor VIII.[A252807] … [L43282] The expression of hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and increase the levels of active factor VIII in blood.

  5. Drug

    Prasterone

    go.drugbank.com/drugs/DB01708
    ApprovedInvestigationalNutraceutical

    In November 2016, DHEA was approved (as Intrarosa) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause … In Canada, a prescription is required to buy DHEA.

    Synonyms: 3β-hydroxyandrost-5-en-17-one, 3-beta-hydroxy-5-androsten-17-one
  6. Drug

    Mipomersen

    go.drugbank.com/drugs/DB05528
    Approved

    Due to this serious risk of liver toxicity, mipomersen sodium is only available to patients under the restricted program called Kynamro Risk Evaluation and Mitigation Strategy program. … Mipomersen is indicated in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipid-lowering medications.

  7. Drug

    Sirolimus

    go.drugbank.com/drugs/DB00877
    ApprovedInvestigational

    [A242372] In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. … rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to

  8. Drug

    Levamisole

    go.drugbank.com/drugs/DB00848
    ApprovedInvestigationalVet approvedWithdrawn

    [A178117, A178123] Levamisole was withdrawn from the American market in 2000 due to its ability to cause serious adverse effects, including agranulocytosis. … [L6232] Prior to this, levamisole was used as an antirheumatic therapy in the 1970s and 1980s for patients with rheumatoid arthritis.

    Products: PVP- LEVAMISOLE POUR-ON SOLUTION 20 %w/v, OBAT CACING NO.17 KAM CEK SAN
  9. Drug

    Veglin

    go.drugbank.com/drugs/DB05890
    Experimental

    Veglin is one of several newly developed non-chemotherapy drugs being tested for possible utilization in the ongoing struggle to combat malignant mesothelioma.

  10. Drug

    Raltegravir

    go.drugbank.com/drugs/DB06817
    ApprovedInvestigational

    Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. … Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.